TRAW

Company Overview — What Does Traws Pharma, Inc. Do?

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Traws Pharma, Inc. (TRAW) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Steven M. Fruchtman and employs approximately 17 people, headquartered in Newtown, Pennsylvania. With a market capitalization of $13M, TRAW is one of the notable companies in the Healthcare sector.

Traws Pharma, Inc. (TRAW) Stock Rating — Reduce (April 2026)

As of April 2026, Traws Pharma, Inc. receives a Reduce rating with a composite score of 26.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TRAW ranks #3,764 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Traws Pharma, Inc. ranks #631 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TRAW Stock Price and 52-Week Range

Traws Pharma, Inc. (TRAW) currently trades at $1.48. The stock lost $0.02 (1.3%) in the most recent trading session. The 52-week high for TRAW is $3.27, which means the stock is currently trading -54.7% from its annual peak. The 52-week low is $0.97, putting the stock 52.6% above its annual trough. Recent trading volume was 34K shares, suggesting relatively thin trading activity.

Is TRAW Overvalued or Undervalued? — Valuation Analysis

Traws Pharma, Inc. (TRAW) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 1.57x, compared to the Healthcare sector average of 23.63x — a discount of 93%. The price-to-book ratio stands at 2.81x, versus the sector average of 2.75x. The price-to-sales ratio is 4.49x, compared to 1.66x for the average Healthcare stock.

At current multiples, Traws Pharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Traws Pharma, Inc. Profitability — ROE, Margins, and Quality Score

Traws Pharma, Inc. (TRAW) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 179.1%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 65.4% versus the sector average of -33.1%.

The operating margin is -8049.7% (sector: -66.1%). Net profit margin stands at 7599.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TRAW Debt, Balance Sheet, and Financial Health

Traws Pharma, Inc. has a debt-to-equity ratio of 174.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.22x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $6M.

TRAW has a beta of 1.21, meaning it is more volatile than the broader market — a $10,000 investment in TRAW would be expected to move 20.8% more than the S&P 500 on any given day. The stability factor score for Traws Pharma, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Traws Pharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Traws Pharma, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.34. Net income for the quarter was $8M. Operating income came in at $-19M.

In Q3 2025, Traws Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.34. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q2 2025, Traws Pharma, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-915,000. Revenue grew 4694.7% year-over-year compared to Q2 2024. Operating income came in at $-1M.

In Q1 2025, Traws Pharma, Inc. reported revenue of $57,000 and earnings per share (EPS) of $2.17. Net income for the quarter was $21M. Revenue grew 1.8% year-over-year compared to Q1 2024. Operating income came in at $-5M.

Over the past 8 quarters, Traws Pharma, Inc. has demonstrated a growth trajectory, with revenue expanding from $56,000 to $3M. Investors analyzing TRAW stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TRAW Dividend Yield and Income Analysis

Traws Pharma, Inc. (TRAW) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TRAW Momentum and Technical Analysis Profile

Traws Pharma, Inc. (TRAW) has a momentum factor score of 32/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

TRAW vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Traws Pharma, Inc. (TRAW) ranks #631 out of 838 stocks based on the Blank Capital composite score. This places TRAW in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TRAW against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TRAW vs S&P 500 (SPY) comparison to assess how Traws Pharma, Inc. stacks up against the broader market across all factor dimensions.

TRAW Next Earnings Date

No upcoming earnings date has been announced for Traws Pharma, Inc. (TRAW) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TRAW? — Investment Thesis Summary

The quantitative profile for Traws Pharma, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Momentum is weak at 32/100, a headwind for near-term performance. High volatility (stability score 22/100) increases portfolio risk.

In summary, Traws Pharma, Inc. (TRAW) earns a Reduce rating with a composite score of 26.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TRAW stock.

Related Resources for TRAW Investors

Explore more research and tools: TRAW vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TRAW head-to-head with peers: TRAW vs AZN, TRAW vs SLGL, TRAW vs VMD.